NASDAQ$RVPH
Reviva Pharmaceuticals Holdi · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Reviva reported financial results for the second quarter ended June 30, 2022 and summarized recent business highlights.
Reviva Pharmaceuticals reported a net loss of $5.3 million for the second quarter of 2022, with cash totaling $19.4 million as of June 30, 2022. The company is focused on advancing the clinical development of brilaroxazine in the Phase 3 RECOVER study for schizophrenia.
- Enrollment is on pace for the ongoing pivotal Phase 3 RECOVER trial.
- Topline data for RECOVER evaluating brilaroxazine for schizophrenia is expected in mid-2023.
- Cash totaled $19.4 million as of June 30, 2022.
- Over 20% of the approximately 400 patients planned already enrolled.
Headline financials
Revenue & EPS history
Reviva · Revenue · Quarterly
$0
Forward guidance
Reviva believes that based on the current operating plan and financial resources, the Company’s cash as of June 30, 2022 will be sufficient to fund its current operating plans through at least March 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2022
-1.2%
Avg return
Earnings day
-0.5%
Avg return
5 days after
+16.7%
Avg return
30 days after
39%
11 / 28 earnings
Positive
+15.8%
Q2 2025
Best reaction
-22.9%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +9.6% | +13.7% | +94.3% | |
| Q3 2025 | -7.3% | -7.9% | +23.0% | |
| Q2 2025 | +15.8% | +11.4% | -5.1% | |
| Q1 2025 | +4.9% | +31.6% | -8.1% | |
| Q4 2024 | +15.0% | +16.0% | +17.1% | |
| Q3 2024 | -9.6% | +0.8% | +108.8% | |
| Q1 2024 | +0.6% | -1.8% | -11.8% | |
| Q4 2023 | -9.8% | -18.2% | -53.7% | |
| Q3 2023 | -17.2% | -33.6% | -37.1% | |
| Q2 2023 | +3.4% | +0.0% | +28.8% | |
| Q1 2023 | +5.4% | -0.5% | -15.6% | |
| Q4 2022 | -10.1% | -5.2% | +47.0% | |
| Q3 2022 | -22.9% | -9.5% | -21.6% | |
| Q2 2022 | +2.8% | +4.9% | +208.5% | |
| Q1 2022 | +15.3% | +17.1% | -20.4% | |
| Q4 2021 | +0.0% | -3.3% | +21.1% | |
| Q3 2021 | -1.3% | -10.3% | -11.4% | |
| Q2 2021 | -6.0% | -4.9% | +18.3% | |
| Q1 2021 | -0.2% | +12.2% | -1.2% | |
| Q4 2020 | -22.3% | -22.6% | -46.5% | |
| Q3 2020 | -0.7% | — | — | |
| Q2 2020 | +0.0% | — | — | |
| Q1 2020 | +0.1% | — | — | |
| Q4 2019 | +0.0% | — | — | |
| Q3 2019 | +0.0% | — | — | |
| Q2 2019 | +0.4% | — | — | |
| Q1 2018 | -0.1% | — | — | |
| Q4 2018 | +0.0% | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro